Viral Vectors & Particles

To order a CRISPR/Cas9 lentivirus to knockout a kinase of interest, select the Gene Symbol of the kinase in the ordering window (for example, select AKT1 if ordering the lentivirus to knockout kinase AKT1). <a href="{{media url="wysiwyg/Kinases/Kinase_Library_-_List_Kinases_Pseudokinases_06-15-2022.xlsx"}}" target="_blank" rel="noopener">Download the table to view all available kinases. The Kinase CRISPR/Cas9 lentivirus is designed to target a specific kinase of interest for knockout. The replication-incompetent, HIV-based, VSV-G pseudotyped lentiviral particles are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. The SIN lentiviral backbone contains the Cas9 gene (Streptococcus pyogenes CRISPR associated protein 9) driven by an EF1a promoter, an sgRNA driven by a U6 promoter, and a puromycin selection marker. Each vial of lentivirus consists of a mixture of lentiviral particles targeting 5 different sgRNAs per gene. The lentivirus integrat

Please note this product may be subject to fees, we invite you to contact your local office. Enhanced green fluorescent protein (eGFP) is a modified (F64L and S65T mutations) version of the native GFP protein isolated from jellyfish (Aequorea victoria), displaying increased fluorescence and more efficient folding. Enhanced GFP Lentiviruses (Inducible TET On) are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses constitutively express eGFP under a tight TRE tetracycline-inducible promoter . After induction with Doxycycline, eGFP expression can easily be visualized and optimized via fluorescence microscopy or flow cytometry. eGFP has an excitation wavelength of 488 nm, an emission wavelength of 509 nm, and extinction coefficient of 55,000 M^-1cm^-1.

The VSV-G Pseudotyped VSV Delta G (Luciferase Reporter) was produced by re-expression of VSV-G as the envelope glycoprotein using the VSV Delta G system in which VSV-G is deleted. The pseudovirions contain the firefly luciferase gene; therefore, the VSV-G mediated cell entry can be measured via luciferase activity. The VSV-G Pseudotyped VSV Delta G (Luciferase Reporter) can be used as a positive control of transduction for other VSV pseudotypes containing the envelope glycoproteins of heterologous viruses in a Biosafety Level 2 facility.

The VSV-G Pseudotyped VSV Delta G (Luciferase Reporter) was produced by re-expression of VSV-G as the envelope glycoprotein using the VSV Delta G system in which VSV-G is deleted. The pseudovirions contain the firefly luciferase gene; therefore, the VSV-G mediated cell entry can be measured via luciferase activity. The VSV-G Pseudotyped VSV Delta G (Luciferase Reporter) can be used as a positive control of transduction for other VSV pseudotypes containing the envelope glycoproteins of heterologous viruses in a Biosafety Level 2 facility.

The Spike (BA.2 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.2 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.2 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 BA.2 variant in a Biosafety Level 2 facility.

The Spike (BA.2 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.2 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.2 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 BA.2 variant in a Biosafety Level 2 facility.

The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike corresponding to the initial strain (Genbank Accession #QHD43416.1) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility. The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6, Calu-3, and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G are preferred for use in cells such as Vero-E6 and Calu-3. The infectivity of VSV-Delta G pseudotypes is restricted to a single round of replication, therefore the pseudotypes can be handled using BSL-2 containment practices.

The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike corresponding to the initial strain (Genbank Accession #QHD43416.1) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility. The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6, Calu-3, and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G are preferred for use in cells such as Vero-E6 and Calu-3. The infectivity of VSV-Delta G pseudotypes is restricted to a single round of replication, therefore the pseudotypes can be handled using BSL-2 containment practices.

Please note this product may be subject to fees, we invite you to contact your local office. Enhanced green fluorescent protein (eGFP) is a modified (F64L and S65T mutations) version of the native GFP protein isolated from jellyfish (Aequorea victoria), with increased fluorescence and more efficient folding. The Enhanced GFP Lentivirus are replication-incompetent, HIV based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. These viruses constitutively express eGFP under a CMV promoter ). eGFP expression and transduction efficiency can easily be verified and optimized via fluorescence microscopy or flow cytometry. eGFP has an excitation wavelength of 488 nm, an emission wavelength of 509 nm, and extinction coefficient of 55,000 M^-1cm^-1.